Literature DB >> 9226176

The development of a model for the homing of multiple myeloma cells to human bone marrow.

M Urashima1, B P Chen, S Chen, G S Pinkus, R T Bronson, D A Dedera, Y Hoshi, G Teoh, A Ogata, S P Treon, D Chauhan, K C Anderson.   

Abstract

Prior in vitro studies have suggested a role of adhesion molecules, bone marrow stromal cells (BMSCs), and cytokines in the regulation of human multiple myeloma (MM) cell growth and survival. Although in vivo models have been developed in severe combined immunodeficient (SCID) mice that support the growth of human MM within the murine BM microenvironment, these xenograft models do not permit a study of the role of adhesion proteins in human MM cell-human BMSC interactions. We therefore established an in vivo model of human MM using SCID mice implanted with bilateral human fetal bone grafts (SCID-hu mice). For the initial tumor innoculum, human MM derived cell lines (1 x 10(4) or 5 x 10(4) ARH-77, OCI-My5, U-266, or RPMI-8226 cells) were injected directly into the BM cavity of the left bone implants in irradiated SCID-hu mice. MM cells engrafted and proliferated in the left human fetal bone implants within SCID-hu mice as early as 4 weeks after injection of as few as 1 x 10(4) MM cells. To determine whether homing of tumor cells occurred, animals were observed for up to 12 weeks after injection and killed to examine for tumor in the right bone implants. Of great interest, metastases to the right bone implants were observed at 12 weeks after the injection of 5 x 10(4) MM cells, without spread of human MM cells to murine BM. Human MM cells were identified on the basis of characteristic histology and monoclonal human Ig. Importantly, monoclonal human Ig and human interleukin-6 (IL-6), but not human IL-1beta or tumor necrosis factor-alpha, were detectable in sera of SCID-hu mice injected with MM cells. In addition, specific monoclonal Ig light chain deposition was evident within renal tubules. This in vivo model of human MM provides for the first time a means for identifying adhesion molecules that are responsible for specific homing of human MM cells to the human, as opposed to murine, BM microenvironment. Moreover, induction of human IL-6 suggests the possibility that regulation of MM cell growth by this cytokine might also be investigated using this in vivo model.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226176

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

Authors:  Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Giulia Perrone; Naoya Miura; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Loredana Santo; Sonia Vallet; Diana Cristea; Elisabetta Calabrese; Gullu Gorgun; Noopur S Raje; Paul Richardson; Nikhil C Munshi; Brian J Lannutti; Kamal D Puri; Neill A Giese; Kenneth C Anderson
Journal:  Blood       Date:  2010-05-26       Impact factor: 22.113

2.  Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.

Authors:  Judith M Runnels; Alicia L Carlson; Costas Pitsillides; Brian Thompson; Juwell Wu; Joel A Spencer; John M J Kohler; AbdelKareem Azab; Anne-Sophie Moreau; Scott J Rodig; Andrew L Kung; Kenneth C Anderson; Irene M Ghobrial; Charles P Lin
Journal:  J Biomed Opt       Date:  2011 Jan-Feb       Impact factor: 3.170

3.  Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

Authors:  Naoya Mimura; Mariateresa Fulciniti; Gullu Gorgun; Yu-Tzu Tai; Diana Cirstea; Loredana Santo; Yiguo Hu; Claire Fabre; Jiro Minami; Hiroto Ohguchi; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Kawano; Maureen French; Martina Blumenthal; Victor Tam; Nathalie L Kertesz; Uriel M Malyankar; Mark Hokenson; Tuan Pham; Qingping Zeng; John B Patterson; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

4.  Progress and Paradigms in Multiple Myeloma.

Authors:  Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

5.  A clinically relevant SCID-hu in vivo model of human multiple myeloma.

Authors:  Pierfrancesco Tassone; Paola Neri; Daniel R Carrasco; Renate Burger; Victor S Goldmacher; Robert Fram; Vidit Munshi; Masood A Shammas; Laurence Catley; Gary S Jacob; Salvatore Venuta; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

6.  Preclinical animal models of multiple myeloma.

Authors:  Seint T Lwin; Claire M Edwards; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2016-02-03

Review 7.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

8.  MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Authors:  Anthony W Gebhard; Priyesh Jain; Rajesh R Nair; Michael F Emmons; Raul F Argilagos; John M Koomen; Mark L McLaughlin; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2013-09-18       Impact factor: 6.261

Review 9.  Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells.

Authors:  Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Tina Vosoughi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-07-20

10.  Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model.

Authors:  Andrei A Postnov; Henk Rozemuller; Viviene Verwey; Henk Lokhorst; Nora De Clerck; Anton C Martens
Journal:  Calcif Tissue Int       Date:  2009-10-09       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.